Coeptis Therapeutics Holdings Past Earnings Performance
Past criteria checks 0/6
Coeptis Therapeutics Holdings's earnings have been declining at an average annual rate of -13.1%, while the Biotechs industry saw earnings growing at 19.3% annually. Revenues have been declining at an average rate of 73.7% per year.
Key information
-13.1%
Earnings growth rate
9.5%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | -73.7% |
| Return on equity | -233.2% |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Coeptis Therapeutics Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -12 | 8 | 3 |
| 30 Jun 24 | 0 | -16 | 10 | 7 |
| 31 Mar 24 | 0 | -16 | 11 | 7 |
| 31 Dec 23 | 0 | -21 | 15 | 7 |
| 30 Sep 23 | 0 | -20 | 15 | 6 |
| 30 Jun 23 | 0 | -20 | 18 | 1 |
| 31 Mar 23 | 0 | -26 | 25 | 0 |
| 31 Dec 22 | 0 | -38 | 34 | 0 |
| 30 Sep 22 | 0 | -37 | 34 | 0 |
| 30 Jun 22 | 0 | -38 | 35 | 0 |
| 31 Mar 22 | 0 | -31 | 28 | 0 |
| 31 Dec 21 | 0 | -13 | 14 | 0 |
| 30 Sep 21 | 0 | -15 | 14 | 0 |
| 30 Jun 21 | 0 | -11 | 9 | 0 |
| 31 Mar 21 | 0 | -9 | 7 | 0 |
| 31 Dec 20 | 0 | -9 | 6 | 0 |
| 31 Dec 19 | 0 | -2 | 3 | 1 |
| 31 Dec 18 | 0 | -2 | 0 | 2 |
Quality Earnings: COEP is currently unprofitable.
Growing Profit Margin: COEP is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: COEP is unprofitable, and losses have increased over the past 5 years at a rate of 13.1% per year.
Accelerating Growth: Unable to compare COEP's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: COEP is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: COEP has a negative Return on Equity (-233.24%), as it is currently unprofitable.